<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02399189</url>
  </required_header>
  <id_info>
    <org_study_id>20150301</org_study_id>
    <nct_id>NCT02399189</nct_id>
  </id_info>
  <brief_title>MT-R Followed by Autologous Stem Cells Transplantation in Newly-diagnosed Primary Central Nervous System Lymphoma</brief_title>
  <official_title>MT-R Followed by Autologous Stem Cells Transplantation in Newly-diagnosed Primary Central Nervous System Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jun Zhu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of chemotherapy with MT-R
      followed by autologous stem cells transplantation in newly-diagnosed primary central nervous
      system lymphoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It's a single center, single arm, prospective clinical trial. Patients younger than 65 years
      old with primary central nervous system lymphoma will received four cycles of chemotherapy
      with rituximab plus high-dose methotrexate and temozolomide as induction therapy, and then
      received consolidation therapy with autologous stem cell transplant for which the
      conditioning regimen is Carmustine plus thiotepa.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">April 2019</completion_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall response rate</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>event-free survival</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>neurotoxicity</measure>
    <time_frame>2 years</time_frame>
    <description>using a battery of cognitive and quality-of-life (QoL) measures</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">39</enrollment>
  <condition>Primary Central Nervous System Lymphoma</condition>
  <arm_group>
    <arm_group_label>R-MT followed by auto-HSCT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>R-MT followed by auto-HSCT Rituximab 375 mg/m2 d1 MTX 3.5g/m2 d2(0.5g/m2 15min,3g/m2 3h） TMZ 100 mg/m2 d2-6 Q21d*4cycles
Auto-HSCT conditioning regimen:
BCNU 400mg/m2 d1; Thiotepa 5mg/kg q12h，d2-3</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>R-MT followed by auto-HSCT</intervention_name>
    <description>Four cycles of Induction therapy: Rituximab 375mg/m2 d1; Methotrexate 3.5g/m2 d2;Temozolomide 100mg/m2 d2-6; for patients who reach a CR, PR, or SD, will proceed to autologous stem cell transplantation: Carmustine 400mg/m2 d1; Thiotepa 5mg/kg q12h, d2-3.</description>
    <arm_group_label>R-MT followed by auto-HSCT</arm_group_label>
    <other_name>Methotrexate(M)</other_name>
    <other_name>Temozolomide(T)</other_name>
    <other_name>Rituximab(R)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  primary central nervous system diffuse large B-cell lymphoma histologically confirmed
             by brain biopsy

          -  ECOG 0-2

          -  Absence of systemic disease as evaluated by chest-abdomen-pelvis CT scan

          -  Leucocytes&gt;3.500/mm3, platelets&gt;130.000/mm3, Bilirubin &lt; 2 mg, transaminases &lt; 2.5 N),
             creatinine &lt; 150 μM/l, creatinine clearance &gt; 50 ml/min/1.73m2

          -  Age 18-65 years

          -  Negative HIV test

          -  Signature of informed consent

        Exclusion Criteria:

          -  prior chemotherapy for primary central nervous system lymphoma

          -  presence of another cancer (excepting basal cell carcinoma of the skin and cervical
             carcinoma in situ )

          -  systemic lymphoma (outside the CNS)

          -  Isolated ocular lymphoma

          -  Immunosuppressed patients (HIV , use of immunosuppressors)

          -  Other uncontrolled or progressive disease compromising shot-term survival

          -  Severe renal or hepatic disease

          -  Patients not legally covered by the French Social Security

          -  Inability to swallow the medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jun Zhu, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Beijing Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>lijuan deng, MD</last_name>
    <phone>1099196109</phone>
    <email>lijuan_deng@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yuqin Song, MD</last_name>
    <phone>1088196109</phone>
    <email>songyuqin622@sina.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Lijuan Deng</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lijuan Deng, MD</last_name>
      <phone>1088196109</phone>
      <email>lijuan_deng@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Yuqin Song, MD</last_name>
      <phone>1088196109</phone>
      <email>songyuqin622@sina.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Correa DD, Maron L, Harder H, Klein M, Armstrong CL, Calabrese P, Bromberg JE, Abrey LE, Batchelor TT, Schiff D. Cognitive functions in primary central nervous system lymphoma: literature review and assessment guidelines. Ann Oncol. 2007 Jul;18(7):1145-51. Epub 2007 Feb 6. Review.</citation>
    <PMID>17284616</PMID>
  </results_reference>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 1, 2015</study_first_submitted>
  <study_first_submitted_qc>March 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2015</study_first_posted>
  <last_update_submitted>April 10, 2015</last_update_submitted>
  <last_update_submitted_qc>April 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 13, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Peking University</investigator_affiliation>
    <investigator_full_name>Jun Zhu</investigator_full_name>
    <investigator_title>Chief of the department of lymphoma</investigator_title>
  </responsible_party>
  <keyword>Primary central nervous system lymphoma</keyword>
  <keyword>rituximab</keyword>
  <keyword>Methotrexate and Temozolomide</keyword>
  <keyword>autologous stem cell transplantation</keyword>
  <keyword>Carmustine and thiotepa</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Thiotepa</mesh_term>
    <mesh_term>Carmustine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

